For ACT017, a « first in class » antithrombotic treatment for Acute Ischemic Stroke.
Paris, Milan, on October 14, 2016 – Acticor Biotech SAS and Mediolanum farmaceutici S.p.A., today announced that they have entered into a research collaboration agreement for Acticor’s project ACT017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum will co-finance research and development of ACT017, currently in preclinical development as a potential next generation antithrombotic treatment for acute ischemic stroke.
Under the terms of the agreement, Acticor received an undisclosed nonrefundable lump sum payment for the preclinical development of ACT017 and is eligible for additional payments to launch clinical development phases 1 and 2. Mediolanum will co-own the results of the collaboration and will acquire marketing rights over two main European countries.
“This agreement further confirms Mediolanum’s strong commitment to identify novel treatments for important underserved medical conditions, such as ACT017” commented its founder and President, Mr. Rinaldo Del Bono.
“We are excited about this great opportunity. ACT017 has shown great potential in preclinical development and will be a strong addition to our growing pipeline” added Alessandro Del Bono, CEO of Mediolanum.
Acticor Biotech’s CEO Gilles Avenard stated: “This agreement validates and strengthens our development strategy for ACT017. We have made excellent progress in our development
program and are very excited to be partnering with Mediolanum, an important player in the European pharmaceutical industry.”
About Ischemic stroke
Stroke is the third cause of death in industrialized countries (6 million deaths worldwide), the second cause of dementia after Alzheimer’s disease and the leading cause of acquired disability in adults. In Europe and in the US, the annual incidence of stroke is estimated at more than 1 500 000 cases. Despite health and economic needs, no treatment is currently satisfactory. In fact, less than 15% of patients can be treated with thrombolysis and no existing antiplatelet drug is suitable for the treatment of acute stroke due to the increased bleeding risk that they all carry. Therefore, it is urgent to propose new therapeutic, innovative, safe and effective strategies for the treatment of stroke.
ACT017, the therapeutic candidate
Acticor is developing ACT017, a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological hemostasis. This limits the bleeding risk associated with its inhibition.
About Acticor Biotech
Acticor Biotech is bio-pharmaceutical company, spin-off of Inserm (U1148 – Bichat Hospital, Paris, France) founded late 2013, dedicated to developing an innovative treatment in the therapy of acute ischemic stroke, a Fab directed against platelet glycoprotein GPVI. Acticor Biotech is built upon the expertise of and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus and Dr Christian Gachet, in two INSERM units, and Professor Philippe Billiald at Paris-Sud University.
Mediolanum farmaceutici is a privately owned pharmaceutical Group, headquartered in Milan and founded in 1972 by Mr. Rinaldo Del Bono. In its 45 years’ history, Mediolanum has submitted applications for 93 inventions, obtaining nearly 700 patents, and has fully developed 4 new pharmaceutical products. In the 2000s, the CEO Alessandro Del Bono launched a new phase of growth, acquiring Istituto Gentili and Neopharmed, now merged into ‘NeopharmedGentili’. Current core business is focused on cardiovascular, osteoporosis and diabetes. The Group – that also includes Cristalfarma, a phytotherapy food supplement company – and the French subsidiary Laboratoires Leurquin Mediolanum, employs about 500 people with an aggregated turnover of about 200 million Euros.
Chief Executive Officer
Mediolanum farmaceutici S.p.A
Business Development Manager
Ottavia Landi di Chiavenna
External Relations Director
Read next in 'Press Releases'
- ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS
- Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital
- Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer
- Acticor Biotech first-in-human clinical trial in healthy volunteers
- Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum